Investigational drug · Phase 2
EB-DART-NK01
Also called: DLL3, CD56 CAR-NK cells
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "EB-DART-NK01"
First trial start
2026
Feb 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EB-DART-NK01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer (SCLC)
- Relapsed/Refractory SCLC
- Extensive-stage SCLC
- SCLC, Extensive Stage
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "EB-DART-NK01" as an intervention, largest first.
Beijing BiotechIndustry
NCT07480213 · 60 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DART-NK01 (DLL3/CD56 CAR-NK cells); Lymphodepleting chemotherapy · For: Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; SCLC, Extensive Stage
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07744256 · 60 participants (planned) · Start Mar 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DART-NK01; Lymphodepleting chemotherapy · For: Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
- Identification of a novel panel of human DLL3-targeting nanobodies with therapeutic potential for small-cell lung cancer.
Yang Z, Jiang Y, Mao L · Biochem Biophys Res Commun 2026
- Single-cell and intercellular communication analyses reveal DLL3 as a key regulator in the glioma tumor microenvironment.
Xie L, Wang H, Pan X, et al. · Mol Ther Nucleic Acids 2026
- Marker-based CRISPR screens identify POU2F1 as a regulator of DLL3 and neuroendocrine identity in small cell lung cancer.
Cunniff PJ, Fitzpatrick C, Bauer J, et al. · NAR Cancer 2026
- Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta.
Shuang Q, Sun M, Lin G, et al. · MAbs 2026
- Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cells.
Mazzanti N, Tamot N, Francese A, et al. · MAbs 2026
- First-in-human, phase I study of clesitamig, a DLL3-targeted CD3×4-1BB trispecific T-cell engager in patients with advanced small-cell lung cancer and other neuroendocrine carcinomas.
Yoshida T, Fowler S, Franjkovic I, et al. · J Immunother Cancer 2026
Also in development for Small Cell Lung Cancer (SCLC)
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- AmrubicinJapan onlyPhase 34 trials
Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.